In a nutshell This phase 2 clinical trial will test the effectiveness of axicabtagene ciloleucel (KTE-C19) in treating relapsed or refractory (unresponsive to treatment) indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the response rate. The details Axicabtagene ciloleucel is a chimeric antigen...
Read More
In a nutshell This study aimed to investigate the outcomes of hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia. This study concluded that hematopoietic cell transplantation is of benefit to patients with primary refractory acute lymphoblastic leukemia. Some background Acute lymphoblastic leukemia (ALL)...
Read MoreIn a nutshell This study examined treatment options for patients who did not respond to induction therapy (treatment to induce complete remission). This study concluded that stem cell transplantation (SCT) or a combination of chemotherapy and other therapies are effective options. Some background Induction therapy in acute myeloid leukemia (AML)...
Read More
In a nutshell This study reported treatment outcomes in children with one or more relapses of acute lymphoblastic leukemia (ALL). Authors reported complete remission (no sign of disease) rates of about 40% after the second relapse or later. Some background ALL is a type of cancer in which the bone marrow makes too many lymphoblasts (a type of...
Read More
In a nutshell This study examined treatment outcomes in patients with chronic myeloid leukemia (CML) treated with second-line tyrosine kinase inhibitors (TKIs). Researchers concluded that treatment responses with second-line TKIs are stable over time. Patients with less favorable treatment outcomes can be identified early during therapy. Some...
Read MoreIn a nutshell This study determined whether a faster course of salvage chemotherapy reduced tumor volume in patients with relapsed or refractory Hodgkin lymphoma. The authors concluded that shorter intervals between SC cycles was safe and effective. Some background Hodgkin lymphoma is considered to be a highly curable form of...
Read More
In a nutshell This trial examined the need for radiotherapy among early-stage Hodgkin lymphoma patients who responded well to chemotherapy. The authors concluded that in these patients, progression-free survival rates were high overall, but were slightly higher with additional radiation. Some background Hodgkin lymphoma is a cancer...
Read More
In a nutshell This study analyzed predictors of treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that testosterone levels before treatment can help predict overall survival in men with mCRPC. Some background Hormone therapy is the standard of care for advanced prostate cancer, including...
Read More
In a nutshell This review analyzed platinum-based drugs in the treatment of advanced castration-resistant prostate cancer. While platinum-based drugs were often associated with various side effects, researchers reported moderate to good treatment effectivity in managing advanced prostate cancer. Some background Hormone therapy is the standard...
Read More
In a nutshell This study examined the benefit of adding apalutamide (JNJ 56021927) to standard hormone therapy in men with castration-resistant prostate cancer (CRPC). Researchers reported preliminary evidence for apalutamide as a safe and effective additional hormone therapy for high-risk CRPC. Some background Hormone therapy is the standard of...
Read More
In a nutshell This review examined the effects of different radiopharmaceuticals in reducing bone pain in advanced prostate cancer. Researchers concluded that radiopharmaceuticals were associated with a significant reduction in bone pain. Some background When prostate cancer spreads outside of the prostate (also called metastatic prostate cancer),...
Read More
In a nutshell The authors aimed to determine the benefit of sequencing docetaxel (Taxotere) and abiraterone (Zytiga) treatment to improve progression-free survival (patients who did not experience cancer growth after treatment) in patients with metastaic (cancer that has spread) hormone-resistant (cancer that does not respond to hormone...
Read More
